NCT06864234 Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA
| NCT ID | NCT06864234 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | VZW Cardiovascular Research Center Aalst |
| Condition | Coronary Arterial Disease (CAD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2025-07-03 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 46 participants in total. It began in 2025-07-03 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn whether beta-blockers can improve coronary blood flow and reduce resistance in patients with angina and no obstructive coronary arteries (ANOCA). The main questions it aims to answer are: * Do beta-blockers improve coronary blood flow in patients with ANOCA? * Do beta-blockers reduce coronary microvascular resistance in these patients? Researchers will compare a beta-blocker to a placebo to see if the medication has measurable effects on coronary circulation. Participants will: * Receive a beta-blocker or a placebo * Undergo specialized heart tests (such as coronary flow and resistance measurements) before and after treatment.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing diagnostic coronary angiography for suspected angina pectoris who are found to have ANOCA i.e. an FFR \>0.80 and no diameter stenosis \>50% * Normal, TIMI 3 flow at angiography * Stable haemodynamics Exclusion Criteria: * Clinical signs or symptoms of congestive heart failure * Severe valvular heart disease requiring either surgical or percutaneous intervention * History of coronary artery bypass grafting * Tortuous coronary anatomy in which wire manipulation could be complex * Heart rate \<60 beats per minute * Systolic blood pressure \<100 mmHg * Unable to give consent * LVEF\<40%
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06864234 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Arterial Disease (CAD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06864234 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06864234 currently recruiting?
Yes, NCT06864234 is actively recruiting participants. Contact the research team at adriaan.wilgenhof@azorg.be for enrollment information.
Where is the NCT06864234 trial being conducted?
This trial is being conducted at Aalst, Belgium.
Who is sponsoring the NCT06864234 clinical trial?
NCT06864234 is sponsored by VZW Cardiovascular Research Center Aalst. The trial plans to enroll 46 participants.